| scholarly article | Q13442814 |
| P50 | author | Francesca Arnoldi | Q56425274 |
| José Luis Slon Campos | Q61101340 | ||
| Oscar R Burrone | Q88601596 | ||
| P2093 | author name string | Marco Bestagno | |
| Jyoti Rana | |||
| Sara Marchese | |||
| Monica Poggianella | |||
| Monica Mossenta | |||
| P2860 | cites work | Zika Virus Outbreak, Bahia, Brazil | Q22330702 |
| The 3.8 Å resolution cryo-EM structure of Zika virus | Q23680595 | ||
| Structure of the thermally stable Zika virus | Q24082710 | ||
| Zika Virus | Q24261255 | ||
| Dengue | Q24570132 | ||
| The global distribution and burden of dengue | Q24628768 | ||
| A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation | Q24672668 | ||
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus | Q24737245 | ||
| Structural basis of potent Zika–dengue virus antibody cross-neutralization | Q24740325 | ||
| Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus | Q25161212 | ||
| Vaccine protection against Zika virus from Brazil | Q25165129 | ||
| Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus | Q26247258 | ||
| Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys | Q26248722 | ||
| Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection | Q26252507 | ||
| The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response | Q26995782 | ||
| Mouse models to study dengue virus immunology and pathogenesis | Q27010151 | ||
| Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes | Q27304342 | ||
| Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells | Q27469935 | ||
| Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein | Q27477718 | ||
| Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus | Q27486788 | ||
| The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection | Q27488224 | ||
| Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody | Q27489654 | ||
| Recognition determinants of broadly neutralizing human antibodies against dengue viruses | Q27697333 | ||
| The complexity of antibody-dependent enhancement of dengue virus infection | Q28250383 | ||
| Cross-reacting antibodies enhance dengue virus infection in humans | Q28281588 | ||
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination | Q28656365 | ||
| Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity | Q29196526 | ||
| Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein | Q29618169 | ||
| Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope | Q30250932 | ||
| Epidemiology of dengue: past, present and future prospects | Q30664159 | ||
| In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system | Q33329274 | ||
| IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity | Q33438726 | ||
| Temperature-dependent folding allows stable dimerization of secretory and virus-associated E proteins of Dengue and Zika viruses in mammalian cells | Q33681310 | ||
| Report of an NIAID workshop on dengue animal models | Q34058747 | ||
| Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop | Q34306877 | ||
| Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial | Q34428943 | ||
| Efficacy of a tetravalent dengue vaccine in children in Latin America. | Q34446032 | ||
| Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease | Q34487028 | ||
| Rapid development of a DNA vaccine for Zika virus | Q34542032 | ||
| Dengue virus neutralization in cells expressing Fc gamma receptors | Q34746693 | ||
| Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans | Q34779065 | ||
| Dissection of antibody specificities induced by yellow fever vaccination | Q34789343 | ||
| Antibody-mediated neutralization of flaviviruses: a reductionist view | Q34999617 | ||
| Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera | Q35294150 | ||
| A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus | Q35654743 | ||
| Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions | Q35982791 | ||
| Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection | Q37123259 | ||
| Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice | Q37137235 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation | Q37605206 | ||
| Animal models of dengue virus infection | Q37987131 | ||
| Nucleic acid (DNA) immunization as a platform for dengue vaccine development | Q38605200 | ||
| Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections | Q38967313 | ||
| Secretion of dengue virus envelope protein ectodomain from mammalian cells is dependent on domain II serotype and affects the immune response upon DNA vaccination | Q39470840 | ||
| Modified mRNA Vaccines Protect against Zika Virus Infection | Q40049416 | ||
| Structural Basis of Zika Virus-Specific Antibody Protection | Q40056291 | ||
| Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. | Q40088326 | ||
| A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice | Q40345843 | ||
| Characterization of neutralizing antibodies to West Nile virus | Q40509400 | ||
| Heterologous flavivirus infection-enhancing antibodies in sera of Nigerians | Q40791231 | ||
| Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system | Q40967469 | ||
| Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen | Q42543247 | ||
| Mammalian cell expression of dimeric small immune proteins (SIP). | Q48048803 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | yellow fever | Q154874 |
| West Nile virus | Q158856 | ||
| Zika virus | Q202864 | ||
| yellow fever virus | Q836749 | ||
| Dengue virus | Q476209 | ||
| dengue virus envelope protein | Q114697797 | ||
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| P304 | page(s) | e0181734 | |
| P577 | publication date | 2017-07-25 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection | |
| P478 | volume | 12 |
| Q47194469 | A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice |
| Q47551011 | Current concerns and perspectives on Zika virus co-infection with arboviruses and HIV. |
| Q55244392 | Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice. |
| Q91562400 | Dengue proteins with their role in pathogenesis, and strategies for developing an effective anti-dengue treatment: A review |
| Q92939082 | Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model |
| Q59352698 | Dengue: a growing threat requiring vaccine development for disease prevention |
| Q56888687 | Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice |
| Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. |
| Q64259781 | Mouse Models of Heterologous Flavivirus Immunity: A Role for Cross-Reactive T Cells |
| Q63248438 | The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis |
Search more.